Giampiero Girolomoni mainly investigates Psoriasis, Immunology, Cytokine, Internal medicine and Cell biology. Psoriasis is a subfield of Dermatology that Giampiero Girolomoni explores. His studies in Dermatology integrate themes in fields like Tacrolimus, Epidemiology, Disease and Rheumatology.
His study in Cytokine is interdisciplinary in nature, drawing from both Inflammation and Keratinocyte. His research in Internal medicine intersects with topics in Gastroenterology, Endocrinology and Cross-sectional study. His work carried out in the field of Cell biology brings together such families of science as CXCL2, Dendritic cell, C-C chemokine receptor type 6, Receptor and Cytotoxic T cell.
Giampiero Girolomoni focuses on Dermatology, Psoriasis, Immunology, Internal medicine and Atopic dermatitis. His biological study spans a wide range of topics, including MEDLINE, Randomized controlled trial, Pathology, Quality of life and Severity of illness. As part of the same scientific family, Giampiero Girolomoni usually focuses on Psoriasis, concentrating on Infliximab and intersecting with Adalimumab.
As part of his studies on Immunology, he often connects relevant subjects like Keratinocyte. His Internal medicine research is multidisciplinary, relying on both Gastroenterology, Endocrinology and Surgery. Giampiero Girolomoni is interested in Dupilumab, which is a branch of Atopic dermatitis.
His primary areas of study are Dermatology, Psoriasis, Atopic dermatitis, Internal medicine and MEDLINE. Giampiero Girolomoni interconnects Differential diagnosis, Methotrexate and Disease in the investigation of issues within Dermatology. His Psoriasis study results in a more complete grasp of Immunology.
Giampiero Girolomoni combines subjects such as Moderate to severe, Observational study and Randomized controlled trial with his study of Atopic dermatitis. His study connects Gastroenterology and Internal medicine. His MEDLINE research is multidisciplinary, incorporating perspectives in Granulomatous Dermatitis, Medical prescription and Severity of illness.
His main research concerns Psoriasis, Dermatology, Atopic dermatitis, Internal medicine and Immunology. His Psoriasis study incorporates themes from Adalimumab, Obesity, Infliximab and Genetic predisposition. His Dermatology study integrates concerns from other disciplines, such as Moderate to severe, Randomized controlled trial, Disease and MEDLINE.
His study looks at the relationship between Disease and topics such as Diabetes mellitus, which overlap with Pathogenesis and Fatty liver. As part of one scientific family, Giampiero Girolomoni deals mainly with the area of Atopic dermatitis, narrowing it down to issues related to the Quality of life, and often Depression. Immunology is closely attributed to Microbiome in his research.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes: synergistic or antagonist effects with IFN-gamma and TNF-alpha.
Cristina Albanesi;Andrea Cavani;Giampiero Girolomoni.
Journal of Immunology (1999)
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).
C Paul;J Cather;M Gooderham;Y Poulin.
British Journal of Dermatology (2015)
Interleukin-17 is produced by both Th1 and Th2 lymphocytes, and modulates interferon-gamma- and interleukin-4-induced activation of human keratinocytes.
Cristina Albanesi;Claudia Scarponi;Andrea Cavani;Monica Federici.
Journal of Investigative Dermatology (2000)
Ultrasound imaging for the rheumatologist.
S Beissert;I Cavazzana;F Mascia;P Meroni.
Clinical and Experimental Rheumatology (2006)
Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial.
Paolo Gisondi;Micol Del Giglio;Vincenzo Di Francesco;Mauro Zamboni.
The American Journal of Clinical Nutrition (2008)
Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis.
Paolo Gisondi;Giovanni Targher;Giacomo Zoppini;Giampiero Girolomoni.
Journal of Hepatology (2009)
CD56brightCD16(-) NK cells accumulate in psoriatic skin in response to CXCL10 and CCL5 and exacerbate skin inflammation.
Chiara Ottaviani;Francesca Nasorri;Chiara Bedini;Ornella de Pità.
European Journal of Immunology (2006)
Granulocyte macrophage colony-stimulating factor is overproduced by keratinocytes in atopic dermatitis. Implications for sustained dendritic cell activation in the skin.
Saveria Pastore;Emanuele Fanales-Belasio;Cristina Albanesi;Luca M. Chinni.
Journal of Clinical Investigation (1997)
Epidemiology of atopic dermatitis in adults: Results from an international survey.
S. Barbarot;S. Auziere;A. Gadkari;G. Girolomoni.
Interleukin-10 Downregulates Anti-Microbial Peptide Expression in Atopic Dermatitis
Michael D. Howell;Natalija Novak;Thomas Bieber;Saveria Pastore.
Journal of Investigative Dermatology (2005)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: